BOCA RATON, FL, July 27 /PRNewswire-FirstCall/ -- SCA in conjunction with Dr. Larry M. Perich and The Perich Eye Center are pleased to announce that Dr. Perich will be one of the first to offer Cell-Enhanced Fat Grafting and stem cell collection and storage services. Traditional autologous fat grafting has been used for decades to treat a variety of soft tissue defects, injuries and disease. The potential of rejection is avoided, and carries little in any potential for infectious disease transmission. Each patient being offered the fat grafting procedure will also be offered SCA's stem cell collection and banking services. There is a growing consensus that adult stem cell therapy, which utilizes a patient's own-collected cells, is the therapy of the future. The core business proposition is based on autologous (your own) stem cells collection that will allow maximum therapeutic values, minimal safety issues, optimal results for patients and cost effectiveness. According to the National Institutes of Health (NIH), there are over 2,300 clinical trials currently underway relating to the use of adult stem cell. Many of these trials involve the treatment or potential cure of numerous serious diseases and conditions, including those that address cardiac disease, autoimmune disorders such as multiple sclerosis, peripheral vascular diseases and age-related musculoskeletal disorders, as well as diabetes, cancer, neurological disease and wound healing. Health conscious consumers can store their stem cells as a means of protecting their future health (the concept of "life banking") with the knowledge that new treatments are being tested now or maybe a few years away. Therefore the AFG procedure aligned with the collection of the patients' stem cell collection and banking will provide for greater service and procedures. Dr. Perich said: autologous fat grafting procedures and stem cell therapy are not only the future of medicine but already have a very large impact on the way patients are treated today. The combination of these treatments and services, through this joint venture, will open up the benefits of AFG and Stem Cell treatment to the current and future patients of both SCA and the Perich Eye Centers and accelerate SCA's expansion into the cosmetic arena". Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements. DATASOURCE: Stem Cell Assurance CONTACT: Investor Relations Contact: George Dubec, Stem Cell Assurance - (561) 362-4142, , http://www.stemcellassurance.com/; http://www.foundhair.com/; http://www.pericheye.com/

Copyright